"That's a predictable market,"
"Even before the change in policies that are being implemented now, vaccines were a difficult business,"
"It's just become that much harder."
The United States supplies disproportionate funding, development resources, and demand that account for roughly 35–40% of global vaccine revenue. Federal vaccine recommendations and higher U.S. prices create a predictable, lucrative market. Recent changes in U.S. health-policy leadership and administration actions have signaled reduced government reliability, including firing vaccine experts, tightening regulatory policies, restricting recommendations, spreading misinformation, halting funding to Gavi, and canceling hundreds of research contracts. Those actions have led vaccine companies to pare back operations, announce layoffs, demerge vaccine divisions, and lose or have grants stripped, exemplified by Moderna's revoked pandemic-flu funding.
Read at The Atlantic
Unable to calculate read time
Collection
[
|
...
]